title: Mild-to-moderate uncomplicated hypertension: further analysis of a cost-effectiveness study of five drugs.
abstract: A cost-effectiveness model was designed to explore the effect of adding a new angiotensin-II inhibitor, telmisartan, to the therapeutic options for treating mild-to-moderate uncomplicated hypertension. Incorporating the cost of drugs, physician visits, and adverse-event treatments, the model concluded that availability of telmisartan on formulary may shorten the mean time and costs to control. The stability of the initial findings over a range of sensitivity analyses lends credence to the model conclusions that availability of telmisartan on formulary improves the therapeutic options of care for hypertension.
authors.affiliation: Research Triangle Institute, 3040 Cornwallis Road, P.O. Box 12194, Research Triangle Park, North Carolina 27709, USA. anke@rti.org
authors.forename: A
authors.initials: A
authors.lastname: Richter
authors.forename: K
authors.initials: K
authors.lastname: Gondek
authors.forename: C
authors.initials: C
authors.lastname: Ostrowski
authors.forename: M
authors.initials: M
authors.lastname: Dombeck
authors.forename: S
authors.initials: S
authors.lastname: Lamb
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000191:economics / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000191:economics / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000191:economics* / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000191:economics* / Q000627:therapeutic use*; D001565:Benzoates / Q000191:economics* / Q000627:therapeutic use*; D001581:Benzothiadiazines; D002121:Calcium Channel Blockers / Q000191:economics / Q000627:therapeutic use; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D004232:Diuretics; D016527:Drug Costs; D005569:Formularies as Topic; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000191:economics; D008329:Managed Care Programs / Q000191:economics; D049993:Sodium Chloride Symporter Inhibitors / Q000191:economics / Q000627:therapeutic use; D000077333:Telmisartan
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D001581:Benzothiadiazines; D002121:Calcium Channel Blockers; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D000077333:Telmisartan